AtriCure Valuation Multiples

AtriCure Overview

About AtriCure

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Founded

2000

HQ

Employees

1.4K

Website

atricure.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $555M

EBITDA: $67M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

AtriCure Financials

AtriCure reported last 12-month revenue of $555M and EBITDA of $67M.

In the same LTM period, AtriCure generated $417M in gross profit, $67M in EBITDA, and had net loss of ($7M).

AtriCure P&L

In the most recent fiscal year, AtriCure reported revenue of $535M and EBITDA of $62M.

AtriCure expects next 12-month revenue of XXX and NTM EBITDA of XXX

AtriCure Stock Performance

AtriCure has current market cap of $2B, and enterprise value of $1B.

AtriCure's stock price is $29.72.

AtriCure Valuation Multiples

AtriCure trades at 2.5x EV/Revenue multiple, and 20.9x EV/EBITDA.

AtriCure Financial Valuation Multiples

As of April 20, 2026, AtriCure has market cap of $2B and EV of $1B.

Equity research analysts estimate AtriCure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

AtriCure has a P/E ratio of (219.1x).

AtriCure Margins & Growth Rates

AtriCure's revenue in the last 12 month grew by 13%.

AtriCure's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.

AtriCure's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

AtriCure's rule of X is 46% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

AtriCure Public Comps

See public comps and valuation multiples for other Medical Devices comps.

AtriCure M&A Activity

AtriCure acquired XXX companies to date.

Last acquisition by AtriCure was on XXXXXXXX, XXXXX. AtriCure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

AtriCure Investment Activity

AtriCure invested in XXX companies to date.

AtriCure made its latest investment on XXXXXXXX, XXXXX. AtriCure invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).